Surgery plan for RAS-mutant colon cancer liver metastases
Part of Cancer, Digestive system clinical trials.
This trial studies an approach to surgically removing liver metastases from colon (or rectal) cancer that has an RAS gene mutation (KRAS or NRAS). If you qualify, you would be evaluated for whether a “complete” (R0) liver operation is planned and technically possible, aiming to improve cancer control by how the liver is cut.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colon or rectal cancer with an RAS gene mutation (KRAS or NRAS)
- Your cancer has spread to the liver (liver metastases), possibly in more than one spot
- Your doctors plan a complete liver tumor removal where no cancer is expected to be left behind (R0 resection)
- Surgery to remove the liver tumors is considered technically possible in your situation
- You are 18 years or older and can give written consent
- You do not have cancer outside the liver (no extrahepatic metastases)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different types of liver surgery for people with colorectal cancer that has spread to the liver and who have specific genetic changes or a right-sided primary tumor. You will be randomly assigned to one surgery type, and researchers will track how well you do over time to see if one approach is better.
This trial tests whether treating liver tumors with surgery or ablation can help people whose colorectal cancer has spread to the liver and other organs. It may be an option if you've had only 1 or 2 types of chemotherapy and your non-liver metastases are stable.
This trial compares liver transplant versus liver surgery for people whose colorectal cancer has spread only to the liver and cannot be removed initially. You would first receive chemotherapy to shrink the tumors, and if they become removable, you may be randomly assigned to have a liver transplant or standard liver surgery.
This trial studies liver transplantation for people with colorectal cancer that has spread to the liver but cannot be surgically removed. It aims to see if transplant can improve outcomes when the cancer is limited to the liver.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This Phase 2 study tests whether delivering chemotherapy directly into the liver (with an IV medicine added, depending on the group) works better than standard chemotherapy given through a vein. It is for people whose colorectal cancer has spread to the liver but can’t be removed by surgery yet.
Hear when a new Colorectal Liver Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.